General InformationAbsci is an AI-driven synthetic biology company based in Seattle, Washington, founded in 2019, with approximately 100-150 employees focused on computationally designed proteins and biologics.
Funding & FinancialsAbsci has raised over $100 million across multiple rounds, including Series C funding in 2023, with backing from investors including Lowercarbon Capital, Playground Global, and others in the deep-tech biotech space.
Leadership & TeamFounded by Sean Ekins and other co-founders with backgrounds in computational chemistry and machine learning; the company is led by executives experienced in biotech and AI-driven drug discovery.
Recent ActivityRecent activity includes expansion of their AI protein design platform, partnerships with pharmaceutical companies for biologics development, and continued advancement of their proprietary machine learning models for therapeutic protein engineering.